# US 2015/0105291 A1 · Method, kit, and apparatus for evaluating ischemic heart disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105291 A1
- Document ID: US20150105291A1
- Status: Published application
- Kind: A1
- Application number: 14/514,523
- Filed: 2014-10-15
- Published: 2015-04-16
- Earliest claimed: 2013-10-15
- Assignees: Hitachi, Ltd.
- Applicants: Hitachi, Ltd.
- Inventors: Hiroko HANZAWA; Takeshi SAKAMOTO; Yuji KUGE
- Web page: https://patentgrep.com/patent/US20150105291A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- C07K 14/472: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C07K 16/36: against blood coagulation factors
- G01N 2333/4716: Complement proteins, e.g. anaphylatoxin, C3a, C5a
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

## Claims

### Claim 1

A method for evaluating an ischemic heart disease, comprising the steps of:
assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and
comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein
it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

### Claim 2 (depends on 1)

The method for evaluating an ischemic heart disease according to claim 1, wherein the seriousness of the ischemic heart disease offers information indicating the determination of the presence of the ischemic heart disease in the test subject and the extent of progression of the heart disease present in the test subject.

### Claim 3 (depends on 1)

The method for evaluating an ischemic heart disease according to claim 1, wherein the step of assaying complement factor H and/or complement factor D comprises quantifying complement factor H and/or complement factor D protein(s) or quantifying mRNA encoding the protein.

### Claim 4 (depends on 1)

The method for evaluating an ischemic heart disease according to claim 1, wherein the step of assaying complement factor H and/or complement factor D employs a substance specifically binding to complement factor H and/or complement factor D protein(s) or is carried out by mass spectrometry or electrophoresis.

### Claim 5

A kit for evaluating an ischemic heart disease, comprising a section that assays complement factor H and/or complement factor D in a sample derived from the blood of a test subject, wherein
it is determined that the seriousness of the ischemic heart disease is high when the concentration of the complement factor H and/or the concentration of the complement factor D falls below a reference value(s).

### Claim 6 (depends on 5)

The kit for evaluating an ischemic heart disease according to claim 5, wherein the section assays complement factor H and/or complement factor D protein(s) or assays mRNA encoding the protein.

### Claim 7 (depends on 5)

The kit for evaluating an ischemic heart disease according to claim 5, wherein the section is a substance specifically binding to complement factor H and/or complement factor D protein(s).

### Claim 8 (depends on 5)

The kit for evaluating an ischemic heart disease according to claim 5, wherein the section is an antibody against the complement factor H and/or the complement factor D, the antibody being immobilized on a solid-phase support.

### Claim 9

An apparatus for evaluating an ischemic heart disease, comprising:
an assay unit that assays complement factor H and/or complement factor D in a sample derived from the blood of a test subject;
a comparison unit that compares the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the assay unit with a reference value(s); and
a determination unit that determines that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

### Claim 10 (depends on 9)

The apparatus for evaluating an ischemic heart disease according to claim 9, wherein the determination unit gains, as the seriousness of the ischemic heart disease, information indicating that the test subject is suspected of having the ischemic heart disease, and information indicating the extent of progression of the heart disease present in the test subject.

### Claim 11 (depends on 9)

The apparatus for evaluating an ischemic heart disease according to claim 9, wherein the assay unit quantifies complement factor H and/or complement factor D protein(s) or quantifies mRNA encoding the protein.

### Claim 12 (depends on 9)

The apparatus for evaluating an ischemic heart disease according to claim 9, wherein the assay unit employs a substance specifically binding to complement factor H and/or complement factor D protein(s) or performs the assay by mass spectrometry or electrophoresis.
